- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David Jackman on Clinical Pathways Discussion at PCOC® 2020
For this year's Patient-Centered Oncology Care® 2020 virtual conference, the discussion on clinical pathways will address how to optimize new data on innovations within oncology.
For this year's Patient-Centered Oncology Care® 2020 virtual conference, the discussion on clinical pathways will address how to optimize new data on innovations within oncology, said David Jackman, MD, senior physician and medical director of Clinical Pathways at the Dana-Farber Cancer Institute.
Transcript
AJMC®: What is the chief message you hope to convey to the participants at Patient-Centered Oncology Care 2020?
Jackman: Health care in this day and age is incredibly exciting, but it’s also incredibly complex. As we think about the torrent of data of new drug approvals and new studies coming forward, we need tools that can help us all sift through the noise and make sense of what belongs and what doesn’t, and how that changes in each given situation so that we can be not just nimble but granular.
Our pathways platform is one way of achieving this or at least moving in the right direction towards this. It’s part of what role pathways play at our institute, as well as other initiatives and other directives. We want that nimbleness to be around not only new medical information, but also frankly things that we learn from our patients as they encounter new side effects or other concerns around each individual regimen.
So, how can we take all of those lessons? The lessons we learned externally, the lessons we learned internally from our doctors and from our patients, and put that all in a nimble and efficient platform. So, that’s something that we’ve strived for with our pathways platform, and something that I think represents just yet 1 additional tool in our armament to wage this war on cancer.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
